119 related articles for article (PubMed ID: 33994313)
1. Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma - An external validation study.
Henriksen SD; Stubbe BE; Madsen PH; Johansen JS; Jensen BV; Hansen CP; Johansen MN; Pedersen IS; Krarup H; Thorlacius-Ussing O
Pancreatology; 2021 May; ():. PubMed ID: 33994313
[TBL] [Abstract][Full Text] [Related]
2. Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma.
Henriksen SD; Madsen PH; Larsen AC; Johansen MB; Drewes AM; Pedersen IS; Krarup H; Thorlacius-Ussing O
Clin Epigenetics; 2016; 8():117. PubMed ID: 27891190
[TBL] [Abstract][Full Text] [Related]
3. Cell-free DNA promoter hypermethylation in plasma as a predictive marker for survival of patients with pancreatic adenocarcinoma.
Henriksen SD; Madsen PH; Larsen AC; Johansen MB; Pedersen IS; Krarup H; Thorlacius-Ussing O
Oncotarget; 2017 Nov; 8(55):93942-93956. PubMed ID: 29212200
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation in plasma-derived cell-free DNA as a prognostic marker for pancreatic adenocarcinoma staging.
Henriksen SD; Madsen PH; Larsen AC; Johansen MB; Pedersen IS; Krarup H; Thorlacius-Ussing O
Int J Cancer; 2017 Dec; 141(12):2489-2497. PubMed ID: 28857158
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocarcinoma.
Stubbe BE; Madsen PH; Larsen AC; Krarup HB; Pedersen IS; Hansen CP; Johansen JS; Henriksen SD; Thorlacius-Ussing O
Pancreatology; 2023 Aug; 23(5):512-521. PubMed ID: 37230892
[TBL] [Abstract][Full Text] [Related]
6. SST gene hypermethylation acts as a pan-cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood-based diagnosis.
Manoochehri M; Wu Y; Giese NA; Strobel O; Kutschmann S; Haller F; Hoheisel JD; Moskalev EA; Hackert T; Bauer AS
Mol Oncol; 2020 Jun; 14(6):1252-1267. PubMed ID: 32243066
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma.
Stubbe BE; Larsen AC; Madsen PH; Krarup HB; Pedersen IS; Lundbye-Christensen S; Hansen CP; Hasselby JP; Johansen AZ; Thorlacius-Ussing O; Johansen JS; Henriksen SD
Front Oncol; 2023; 13():1211292. PubMed ID: 37333823
[TBL] [Abstract][Full Text] [Related]
8. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.
Debernardi S; O'Brien H; Algahmdi AS; Malats N; Stewart GD; Plješa-Ercegovac M; Costello E; Greenhalf W; Saad A; Roberts R; Ney A; Pereira SP; Kocher HM; Duffy S; Blyuss O; Crnogorac-Jurcevic T
PLoS Med; 2020 Dec; 17(12):e1003489. PubMed ID: 33301466
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of promoter methylation status of tumor suppressor genes in circulating DNA of pancreatic cancer patients.
Singh N; Rashid S; Rashid S; Dash NR; Gupta S; Saraya A
J Cancer Res Clin Oncol; 2020 Apr; 146(4):897-907. PubMed ID: 32146565
[TBL] [Abstract][Full Text] [Related]
10. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
Nakamura K; Zhu Z; Roy S; Jun E; Han H; Munoz RM; Nishiwada S; Sharma G; Cridebring D; Zenhausern F; Kim S; Roe DJ; Darabi S; Han IW; Evans DB; Yamada S; Demeure MJ; Becerra C; Celinski SA; Borazanci E; Tsai S; Kodera Y; Park JO; Bolton JS; Wang X; Kim SC; Von Hoff D; Goel A
Gastroenterology; 2022 Nov; 163(5):1252-1266.e2. PubMed ID: 35850192
[TBL] [Abstract][Full Text] [Related]
11. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood.
Eissa MAL; Lerner L; Abdelfatah E; Shankar N; Canner JK; Hasan NM; Yaghoobi V; Huang B; Kerner Z; Takaesu F; Wolfgang C; Kwak R; Ruiz M; Tam M; Pisanic TR; Iacobuzio-Donahue CA; Hruban RH; He J; Wang TH; Wood LD; Sharma A; Ahuja N
Clin Epigenetics; 2019 Apr; 11(1):59. PubMed ID: 30953539
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB
J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
[TBL] [Abstract][Full Text] [Related]
13. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
Balasenthil S; Huang Y; Liu S; Marsh T; Chen J; Stass SA; KuKuruga D; Brand R; Chen N; Frazier ML; Jack Lee J; Srivastava S; Sen S; McNeill Killary A
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376184
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma.
Zhao X; Cao D; Ren Z; Liu Z; Lv S; Zhu J; Li L; Lang R; He Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32701143
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer.
Nishizawa N; Harada H; Kumamoto Y; Kaizu T; Katoh H; Tajima H; Ushiku H; Yokoi K; Igarashi K; Fujiyama Y; Okuwaki K; Iwai T; Watanabe M; Yamashita K
Cancer Sci; 2019 Sep; 110(9):2846-2855. PubMed ID: 31325200
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of cell-free DNA as a biomarker for pancreatic malignancies.
Sikora K; Bedin C; Vicentini C; Malpeli G; D'Angelo E; Sperandio N; Lawlor RT; Bassi C; Tortora G; Nitti D; Agostini M; Fassan M; Scarpa A
Int J Biol Markers; 2015 Feb; 30(1):e136-41. PubMed ID: 24832178
[TBL] [Abstract][Full Text] [Related]
17. CA 19-9 but Not IGF-1/IGFBP-2 Is a Useful Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC) and Chronic Pancreatitis (CP) Differentiation.
Wlodarczyk B; Durko L; Wlodarczyk P; Talar-Wojnarowska R; Malecka-Wojciesko E
J Clin Med; 2023 Jun; 12(12):. PubMed ID: 37373743
[TBL] [Abstract][Full Text] [Related]
18. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma.
Yu S; Li Y; Liao Z; Wang Z; Wang Z; Li Y; Qian L; Zhao J; Zong H; Kang B; Zou WB; Chen K; He X; Meng Z; Chen Z; Huang S; Wang P
Gut; 2020 Mar; 69(3):540-550. PubMed ID: 31562239
[TBL] [Abstract][Full Text] [Related]
19. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions.
Bararia A; Dey S; Gulati S; Ghatak S; Ghosh S; Banerjee S; Sikdar N
Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):205-217. PubMed ID: 32312637
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA.
Wu H; Guo S; Liu X; Li Y; Su Z; He Q; Liu X; Zhang Z; Yu L; Shi X; Gao S; Wang H; Pan Y; Ma C; Liu R; Dai M; Jin G; Liang Z
BMC Med; 2022 Nov; 20(1):458. PubMed ID: 36434648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
